Investors & Media

Transformative science, targeted medicines

We are working to advance a deep pipeline of precision therapies, designed to allow patients to live longer, better lives. Our approach combines world-leading expertise in protein kinases with sound execution and an intense focus on discovery.

SEC filing details

Document Details

Form
4
Filing Date
Jun 4, 2021
Document Date
Jun 2, 2021
Form Description
Statement of changes in beneficial ownership of securities
Filing Group
3,4,5
Company
Blueprint Medicines Corp.
Issuer
Blueprint Medicines Corp
Filer
Seely Lynn